Company news
Actuate Therapeutics, Inc. news in 2025
Actuate Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026
December 18, 2025
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
December 15, 2025
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
September 22, 2025
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
September 11, 2025
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
September 10, 2025
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
September 9, 2025
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
August 25, 2025
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
August 6, 2025
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
July 17, 2025
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
June 24, 2025
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
June 20, 2025
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 16, 2025
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
June 2, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
May 31, 2025
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
May 22, 2025
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
May 7, 2025
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
May 6, 2025
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025
April 30, 2025
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 23, 2025
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025
April 17, 2025
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
February 25, 2025
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
January 6, 2025
Decks in 2025
- Investor Presentation (November 2025)
Investor deck · 29 slides · November 2025
- Investor Presentation (August 2025)
Investor deck · 25 slides · August 2025
- Investor Presentation (May 2025)
Investor deck · 25 slides · May 31, 2025
- Investor Presentation (March 2025)
Investor deck · 21 slides · March 2025
- Investor Presentation (January 2025)
Investor deck · 21 slides · January 2025